Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -24.23% | -59.39% | -77.08% | -76.37% | -75.77% |
| Total Other Revenue | -9.88% | -9.97% | -13.45% | -20.32% | -25.33% |
| Total Revenue | -16.69% | -38.10% | -53.36% | -59.25% | -62.43% |
| Cost of Revenue | -1.28% | -5.42% | -12.16% | -15.88% | -18.59% |
| Gross Profit | -5.04% | -11.71% | -13.86% | -29.15% | -56.06% |
| SG&A Expenses | -6.13% | 0.32% | 2.73% | 4.12% | 6.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.80% | -3.74% | -8.06% | -10.54% | -11.99% |
| Operating Income | -0.66% | -7.29% | -9.60% | -18.49% | -32.19% |
| Income Before Tax | -10.52% | -9.27% | -4.29% | -16.39% | -36.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.52% | -9.27% | -4.29% | -16.39% | -36.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.52% | -9.27% | -4.29% | -16.39% | -36.03% |
| EBIT | -0.66% | -7.29% | -9.60% | -18.49% | -32.19% |
| EBITDA | -1.15% | -8.24% | -10.99% | -20.64% | -35.68% |
| EPS Basic | 0.32% | 1.56% | 6.03% | -8.35% | -31.18% |
| Normalized Basic EPS | 0.29% | 1.51% | 6.03% | -8.31% | -31.13% |
| EPS Diluted | 0.95% | 1.72% | 5.87% | -8.44% | -31.08% |
| Normalized Diluted EPS | 0.29% | 1.51% | 6.03% | -8.31% | -31.13% |
| Average Basic Shares Outstanding | 10.65% | 10.59% | 10.54% | 7.35% | 4.16% |
| Average Diluted Shares Outstanding | 10.65% | 10.59% | 10.54% | 7.35% | 4.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |